Trademark: 79339202
Status Date
Tuesday, January 3, 2023
Registration Number
6938347
Registration Date
Tuesday, January 3, 2023
Filing Date
Tuesday, February 1, 2022
Published for Opposition
Tuesday, October 18, 2022
9 Downloadable computer software for scientific laboratory research and commercial use for applications with monoclonal or trimeric antibodies used to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, namely, software for an algorithm to generate antibody sequences
5 Pharmaceutical preparations based on human monoclonal or trimeric antibodies and derivatives thereof for treating cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, for use in related diagnostic or therapeutic use, and for use as medical diagnostic assays for testing of body fluids or tissues, for use in disease detection, including, cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases
1 Biochemicals, namely, monoclonal and trimeric antibodies and derivatives thereof for in-vivo or in-vitro scientific research and development to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases and for use in laboratories, diagnostics and analytics for scientific or research use
45 Legal services in the field of patent exploitation, namely, patent licensing; licensing of intellectual property in the field of monoclonal and trimeric antibodies for laboratories, diagnostics and analytics for scientific or research use
42 Medical and scientific research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; medical research services, namely, protein engineering in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; pharmaceutical product development in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; industrial research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; and contract research services in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; computer programming for acquisition and processing of medical data in the context of medical-scientific research, development and therapy with monoclonal or trimeric antibodies and their derivatives
May 17, 2023
Final Decision Transaction Processed By Ib
Apr 20, 2023
Final Disposition Notice Sent To Ib
Apr 20, 2023
Final Disposition Processed
Apr 3, 2023
Final Disposition Notice Created, To Be Sent To Ib
Jan 3, 2023
Notice Of Registration Confirmation Emailed
Jan 3, 2023
Registered-Principal Register
Oct 18, 2022
Official Gazette Publication Confirmation E-Mailed
Oct 18, 2022
Published For Opposition
Sep 28, 2022
Notification Of Notice Of Publication E-Mailed
Sep 21, 2022
Refusal Processed By Ib
Sep 13, 2022
Approved For Pub - Principal Register
Sep 10, 2022
Teas/Email Correspondence Entered
Sep 9, 2022
Correspondence Received In Law Office
Sep 9, 2022
Teas Response To Office Action Received
Sep 1, 2022
Non-Final Action Mailed - Refusal Sent To Ib
Aug 31, 2022
Refusal Processed By Mpu
Aug 3, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Aug 2, 2022
Non-Final Action Written
Jul 28, 2022
Assigned To Examiner
May 3, 2022
Application Filing Receipt Mailed
Apr 29, 2022
New Application Office Supplied Data Entered
Apr 28, 2022
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
